Lantern Pharma Files 8-K on Financials
Ticker: LTRN · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Lantern Pharma dropped an 8-K on March 18th detailing their financial condition and operations.
AI Summary
Lantern Pharma Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Dallas, Texas.
Why It Matters
This 8-K filing provides crucial updates on Lantern Pharma's financial performance and operational status, which is important for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial information and does not indicate any unusual or high-risk events.
Key Players & Entities
- Lantern Pharma Inc. (company) — Registrant
- March 18, 2024 (date) — Date of earliest event reported
- Dallas, Texas (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Lantern Pharma Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 18, 2024.
Where are Lantern Pharma Inc.'s principal executive offices located?
Lantern Pharma Inc.'s principal executive offices are located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas, 75201.
What is Lantern Pharma Inc.'s state of incorporation?
Lantern Pharma Inc. is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 46-3973463.
Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-18 16:05:37
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value LTRN The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 75KB
- ex99-2.htm (EX-99.2) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- ex99-2_001.jpg (GRAPHIC) — 175KB
- ex99-2_002.jpg (GRAPHIC) — 743KB
- ex99-2_003.jpg (GRAPHIC) — 301KB
- ex99-2_004.jpg (GRAPHIC) — 256KB
- ex99-2_005.jpg (GRAPHIC) — 289KB
- ex99-2_006.jpg (GRAPHIC) — 309KB
- ex99-2_007.jpg (GRAPHIC) — 320KB
- ex99-2_008.jpg (GRAPHIC) — 232KB
- ex99-2_009.jpg (GRAPHIC) — 130KB
- ex99-2_010.jpg (GRAPHIC) — 135KB
- ex99-2_011.jpg (GRAPHIC) — 406KB
- ex99-2_012.jpg (GRAPHIC) — 330KB
- ex99-2_013.jpg (GRAPHIC) — 329KB
- ex99-2_014.jpg (GRAPHIC) — 390KB
- ex99-2_015.jpg (GRAPHIC) — 357KB
- ex99-2_016.jpg (GRAPHIC) — 261KB
- ex99-2_017.jpg (GRAPHIC) — 341KB
- ex99-2_018.jpg (GRAPHIC) — 299KB
- ex99-2_019.jpg (GRAPHIC) — 124KB
- 0001493152-24-010303.txt ( ) — 8223KB
- ltrn-20240318.xsd (EX-101.SCH) — 3KB
- ltrn-20240318_lab.xml (EX-101.LAB) — 33KB
- ltrn-20240318_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lantern Pharma Inc., A Delaware Corporation Dated: March 18, 2024 By: /s/ David R. Margrave David R. Margrave, Chief Financial Officer 3